Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New England Journal of Medicine Publishes Pivotal Results Evaluating Sunovion\u2019s SEP-363856 for the Treatment of Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","amount":"$890.0 million","upfrontCash":"$270.0 million","newsHeadline":"Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development and Commercialization Collaboration","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Otsuka and Sumitomo Revise License Agreement","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Sunovion Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka and Sunovion Initiate Clinical Development of Ulotaront for the Adjunctive Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Otsuka America Pharmaceutical, Inc.","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 DIAMOND 1 and DIAMOND 2 Clinical Studies Evaluating Ulotaront in Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals for Ulotaront

    Menu

    Ulotaront

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Sumitomo Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Otsuka and Sumitomo Revise License Agreement

              Details:

              Under the license agreement, Otsuka holds exclusive rights to develop, manufacture, and commercialize SEP-363856 (ulotaront), TAAR1 agonist. It is being evaluated with the patient for the treatment of Schizophrenia.

              Lead Product(s): Ulotaront

              Therapeutic Area: Psychiatry/Psychology Product Name: SEP-363856

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Otsuka Pharmaceutical

              Deal Size: $30.0 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement March 15, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sumitomo

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 DIAMOND 1 and DIAMOND 2 Clinical Studies Evaluating Ulotaront in Schizophrenia

              Details:

              SEP-363856 (ulotaront) is a TAAR1 agonist with 5-HT1A agonist activity, is currently under investigation for the treatment of schizophrenia, generalized anxiety disorder and the adjunctive treatment of MDD with additional indications under consideration.

              Lead Product(s): Ulotaront

              Therapeutic Area: Psychiatry/Psychology Product Name: SEP-363856

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Otsuka Pharmaceutical

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 31, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sunovion Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder

              Details:

              SEP-363856 (ulotaront) is a TAAR1 agonist with 5-HT1A agonist activity, is currently under investigation for the treatment of schizophrenia, generalized anxiety disorder and the adjunctive treatment of MDD with additional indications under consideration.

              Lead Product(s): Ulotaront

              Therapeutic Area: Psychiatry/Psychology Product Name: SEP-363856

              Highest Development Status: Phase II/ Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Otsuka America Pharmaceutical, Inc.

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 26, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Otsuka Pharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Otsuka and Sunovion Initiate Clinical Development of Ulotaront for the Adjunctive Treatment of Major Depressive Disorder

              Details:

              Ulotaront (SEP-363856), a TAAR1 agonist with 5-HT1A agonist activity, is currently under investigation for the treatment of schizophrenia as well as the adjunctive treatment of MDD, with additional indications under consideration.

              Lead Product(s): Ulotaront

              Therapeutic Area: Psychiatry/Psychology Product Name: SEP-363856

              Highest Development Status: Phase II/ Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Sunovion Pharmaceuticals

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sunovion Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development and Commercialization Collaboration

              Details:

              The collaboration will focus on solutions to address areas of unmet medical need by advancing four promising compounds―ulotaront (SEP-363856), SEP-4199, SEP-378614 and SEP-380135―that address serious neuropsychiatric disorders.

              Lead Product(s): Ulotaront

              Therapeutic Area: Psychiatry/Psychology Product Name: SEP-363856

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Otsuka Pharmaceutical

              Deal Size: $890.0 million Upfront Cash: $270.0 million

              Deal Type: Collaboration September 30, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sunovion Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              New England Journal of Medicine Publishes Pivotal Results Evaluating Sunovion’s SEP-363856 for the Treatment of Schizophrenia

              Details:

              Significantly greater improvement in the Positive and Negative Symptom Scale was demonstrated in schizophrenia patients treated with SEP-363856, a TAAR1 agonist, compared to placebo.

              Lead Product(s): Ulotaront

              Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 15, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY